Molecular characterization of synovial sarcoma in children and adolescents: Evidence of Akt activation

Translational Oncology

Volumn 1, Issue 2, 2008, Pages 95-101

  Bozzi, Fabio ^a   Ferrari, Andrea ^a   Negri, Tiziana ^a   Conca, Elena ^a   Luca, Da Riva ^a   Losa, Marco ^a   Casieri, Paola ^a   Orsenigo, Marta ^a   Lampis, Andrea ^a   Meazza, Cristina ^a   Casanova, Michela ^a   Pierotti, Marco A ^a   Tamborini, Elena ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649698279     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.08121     Document Type: Article

References (23)

1. Allander SV, Illei PB, Chen Y, Antonescu CR, Bittner M, Ladanyi M, and Meltzer PS (2002). Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161, 1587-1595.
2. Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, and Baker L (2005). Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103, 830-838.
3. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, Dirisina R, Porter-Westpfahl KS, Hembree M, Johnson T, et al. (2007). PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 39, 189-198.
4. Pretto D, Barca R, Rivera J, Neel N, Gustavson MD, and Eid JE (2006). The synovial sarcoma translocation protein SYT-SSX2 recruits β-catenin to the nucleus and associates with it in an active complexes. Oncogene 25, 3661-3669.
5. Saito T, Oda Y, Sugimachi K, Kawaguchi K, Tamiya S, Tanaka K, Matsuda S, Sakamoto A, Iwamoto Y, and Tsuneyoshi M (2001). E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features. Am J Pathol 159, 2117-2124.
6. Saito T, Oda Y, Sakamoto A, Kawaguchi K, Tanaka K, Matsuda S, Tamiya S, Iwamoto Y, and Tsuneyoshi M (2002). APC mutations in synovial sarcoma. J Pathol 196, 445-449.
7. Nakamura Y (1997). Cleaning up on β-catenin. Nat Genet 3, 499-500.
8. Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, Gronchi A, Pastorino U, Pierotti MA, et al. (2007). Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol 212, 227-235.
9. Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, Bossi P, et al. (2006). Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 12, 6643-6651.
10. Mancuso T, Mezzelani A, Riva C, Fabbri A, Dal Bo L, Sampietro G, Perego P, Casali P, Zunino F, Sozzi G, et al. (2000). Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest 80, 805-813.
11. Tamborini E, Papini D, Mezzelani A, Riva C, Azzarelli A, Sozzi G, Pierotti MA, and Pilotti S (2001). c-KIT and c-KIT ligand (SCF) in synovial sarcoma (SS): an mRNA expression analysis in 23 cases. Br J Cancer 85, 405-411.
12. Surace C, Panagopoulos I, Palsson E, Rocchi M, Mandahl N, and Mertens F (2004). A novel FISH assay for SS18-SSX fusion type in synovial sarcoma. Lab Invest 84, 1185-1192.
13. Winer J, Jung CK, Shackel I, and Wiiliams PM (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 270, 41-49.
14. Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, et al. (2007). Cyclooxygenase-2 and plateletderived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res 13, 5034-5040.
15. Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, Casali PG, Pierotti MA, and Pilotti S (2004). Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res 10, 938-943.
16. Antonescu CR, Leung DH, Dudas M, Ladanyi M, Brennan M, Woodruff JM, and Cordon-Cardo C (2000). Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol 156, 977-983.
17. Horvai AE, Kramer MJ, and O'Donnell R (2006). β-Catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med 130, 792-798.
18. Bode B, Frigerio S, Behnke S, Senn B, Odermatt B, Zimmermann DR, and Moch H (2006). Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 19, 541-547.
19. Lopez-Guerrero JA, Navarro S, Noguera R, Carda C, Farinas SC, Pellin A, and Llombart Bosch A (2005). Mutational analysis of the c-KIT and PDGFRα in a series of molecularly well-characterized synovial sarcomas. Diagn Mol Pathol 14, 134-138.
20. Saito T, Oda Y, Yamamoto H, Kawaguchi K, Tanaka K, Matsuda S, Iwamoto Y, and Tsuneyoshi M (2006). Nuclear β-catenin correlates with cyclin D1 expression in spindle and pleomorphic sarcomas but not in synovial sarcoma. Hum Pathol 37, 689-697.
21. Blay JY, Ray-Coquard I, Alberti L, and Ranchère D (2004). Targeting other abnormal signalling pathways in sarcoma: EGFR in synovial sarcoma, PPARgamma in liposarcomas. Cancer Treat Res 120, 151-167.
22. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, et al. (2007). Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 4, 752-760.
23. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, and Casali PG (2004). Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101, 627-634.